Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Association of Early Changes in Dual-Layer Detector CT Parameters With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
  2. VHL Mutation Analysis in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease
  3. HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib
  4. Role of PD-L1 Status in mRCC Treated With First-Line Immune-Based Combinations
  5. Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell RCC
  6. Comparing iRECIST-Based and Free Text Reporting of CT Scans for Monitoring Metastatic Renal Cell Carcinoma
  7. A Simple-to-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma
  8. Sunitinib as a Second-Line Therapy in Patients With Metastatic RCC After Immune Checkpoint Inhibitor–Based Combination Therapy
  9. Effectiveness and Safety of Nivolumab Combination Therapy vs Targeted Drug Therapy in Metastatic Renal Cell Carcinoma
  10. Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma in Patients With Haematuria

Elsewhere

Recently Updated